

North America Anti-Obesity Drugs Market Size and Forecast (2021 - 2031)

<https://marketpublishers.com/r/N6474F5093FAEN.html>

Date: January 2026

Pages: 205

Price: US\$ 3,450.00 (Single User License)

ID: N6474F5093FAEN

Abstracts

The North America Anti-Obesity Drugs Market is projected to grow significantly, reaching approximately US\$ 147,317.2 million by 2031, up from US\$ 12,583.7 million in 2024, with an estimated compound annual growth rate (CAGR) of 34.5% from 2025 to 2031.

Executive Summary and Market Analysis

The North American anti-obesity drugs market encompasses the United States, Canada, and Mexico, and is expected to capture a substantial portion of the global market. The growth in this region is driven by increasing obesity rates, heightened health awareness, and advancements in pharmaceutical research. The prevalence of obesity in North America is notably high, attributed to sedentary lifestyles, poor dietary choices, and genetic predispositions, which has led to a rising demand for effective weight management solutions. Additionally, government and healthcare initiatives aimed at obesity prevention and treatment are further propelling market growth. Improved healthcare access and insurance coverage for obesity treatments also encourage patients to adopt these medications. Innovations in technology and the development of safer, more effective drugs, particularly GLP-1 receptor agonists, have significantly improved treatment outcomes, earning the trust of healthcare providers and patients. Furthermore, increased investment in research and development by pharmaceutical companies, along with strategic partnerships for drug development and marketing, is contributing to the rapid expansion of the market. These factors position North America as a key player in the global anti-obesity drug market.

Strategic Insights

Market Segmentation Analysis

By Type: The market is divided into Prescription Drugs and OTC Drugs, with Prescription Drugs holding the largest market share in 2024.

By Mechanism of Action: Segmented into Centrally Acting Drugs, Peripherally Acting Drugs, and Others, with Centrally Acting Drugs leading in market share in 2024.

By Drug Class: Includes GLP-1 Agonists, Lipase Inhibitors, MC4R Agonists, and Others, where GLP-1 Agonists dominate the market in 2024.

By GLP-1 Agonist: Further segmented into Semaglutide, Liraglutide, and Tirzepatide (Zepbound), with Semaglutide having the largest share in 2024.

By Application: Categories include Appetite Suppression, Inhibition of Fat Absorption, Metabolic Enhancement, and Combination, with Appetite Suppression leading in 2024.

By Route of Administration: Divided into Oral and Parenteral, with Parenteral being the most prevalent in 2024.

By Distribution Channel: Includes Hospital Pharmacies, Online Channels, and Retail Pharmacies, with Hospital Pharmacies holding the largest share in 2024.

Market Outlook

The global anti-obesity drugs market is primarily driven by the increasing prevalence of obesity. As obesity rates rise due to lifestyle factors and genetic influences, the demand for effective medical interventions is growing. This trend is prompting patients and healthcare providers to seek pharmacological solutions alongside lifestyle modifications. Consequently, pharmaceutical companies are investing heavily in the development and marketing of anti-obesity drugs. The World Health Organization (WHO) reports that the global prevalence of obesity has more than doubled since 1990, with 2.5 billion adults classified as overweight and over 890 million as obese in 2022. The prevalence of obesity is expected to rise from 14% in 2023 to 24% by 2035, affecting nearly 2 billion individuals. The economic burden of obesity is also significant, with costs projected to exceed US\$ 4 trillion by 2035, accounting for about 3% of global GDP.

Country Insights

The North American market is segmented into the United States, Canada, and Mexico, with the United States holding the largest market share in 2024. According to the National Health and Nutrition Examination Survey, the obesity prevalence in U.S. adults was 40.3% from August 2021 to August 2023, with higher rates among those aged 40-59. This increase in obesity rates has led to a rise in related health issues, such as type 2 diabetes and cardiovascular diseases, driving demand for effective anti-obesity medications.

Key pharmaceutical companies, such as Novo Nordisk and Eli Lilly, have introduced innovative treatments that have transformed the market. Novo Nordisk's semaglutide-based drugs, Ozempic and Wegovy, are widely prescribed for diabetes and obesity management. Eli Lilly's tirzepatide, marketed as Mounjaro and Zepbound, has also gained traction, with promising results from clinical trials for new weight-loss drugs.

Company Profiles

Key players in the North America Anti-Obesity Drugs Market include GSK Plc, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd, Novo Nordisk AS, Eli Lilly and Co, Sun Pharmaceutical Industries Ltd, VIVUS LLC, Currax Pharmaceuticals LLC, AdvaCare Pharma USA LLC, and Rhythm Pharmaceuticals Inc. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and offer innovative products.

Contents

1. INTRODUCTION

- 1.1 Report Guidance
- 1.2 Market Segmentation

2. EXECUTIVE SUMMARY

- 2.1 Key Insights
- 2.2 Market Attractiveness

3. RESEARCH METHODOLOGY

- 3.1 Secondary Research
- 3.2 Primary Research
 - 3.2.1 Hypothesis formulation:
 - 3.2.2 Macroeconomic factor analysis:
 - 3.2.3 Developing base number:
 - 3.2.4 Data Triangulation:
 - 3.2.5 Country-level data:

4. ANTI-OBESITY DRUGS MARKET LANDSCAPE

- 4.1 Market Overview
- 4.2 PEST Analysis

5. NORTH AMERICA ANTI-OBESITY DRUGS MARKET - KEY MARKET DYNAMICS

- 5.1 Market Drivers
- 5.2 Market Restraints
- 5.3 Market Opportunities
- 5.4 Future Trends
- 5.5 Impact of Drivers and Restraints:

6. ANTI-OBESITY DRUGS MARKET - NORTH AMERICA MARKET ANALYSIS

- 6.1 North America Anti-Obesity Drugs Market Revenue (US\$ Million), 2024 - 2031
- 6.2 North America Anti-Obesity Drugs Market Forecast and Analysis

7. NORTH AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY TYPE

7.1 Prescription Drugs

7.1.1 Overview

7.1.2 Prescription Drugs: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

7.2 OTC Drugs

7.2.1 Overview

7.2.2 OTC Drugs: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

8. NORTH AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY MECHANISM OF ACTION

8.1 Centrally Acting Drugs

8.1.1 Overview

8.1.2 Centrally Acting Drugs: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

8.2 Peripherally Acting Drugs

8.2.1 Overview

8.2.2 Peripherally Acting Drugs: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

8.3 Others

8.3.1 Overview

8.3.2 Others: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

9. NORTH AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY DRUG CLASS

9.1 GLP-1 Agonist

9.1.1 Overview

9.1.2 GLP-1 Agonist: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

9.2 Lipase Inhibitors

9.2.1 Overview

9.2.2 Lipase Inhibitors: North America Anti-Obesity Drugs Market - Revenue and

Forecast, 2021 - 2031 (US\$ Million)

9.3 MC4R agonist

9.3.1 Overview

9.3.2 MC4R agonist: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

9.4 Others

9.4.1 Overview

9.4.2 Others: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

10. NORTH AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY GLP-1 AGONIST

10.1 Semaglutide

10.1.1 Overview

10.1.2 Semaglutide: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

10.2 Liraglutide

10.2.1 Overview

10.2.2 Liraglutide: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

10.3 Tirzepatide (Zepbound)

10.3.1 Overview

10.3.2 Tirzepatide (Zepbound): North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

11. NORTH AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY APPLICATION

11.1 Appetite Suppression

11.1.1 Overview

11.1.2 Appetite Suppression: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

11.2 Inhibition of Fat Absorption or Digestive Enzymes

11.2.1 Overview

11.2.2 Inhibition of Fat Absorption or Digestive Enzymes: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

11.3 Metabolic Enhancement

11.3.1 Overview

11.3.2 Metabolic Enhancement: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

11.4 Combination

11.4.1 Overview

11.4.2 Combination: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

12. NORTH AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY ROUTE OF ADMINISTRATION

12.1 Oral

12.1.1 Overview

12.1.2 Oral: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

12.2 Parenteral

12.2.1 Overview

12.2.2 Parenteral: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

13. NORTH AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY DISTRIBUTION CHANNEL

13.1 Hospital Pharmacies

13.1.1 Overview

13.1.2 Hospital Pharmacies: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

13.2 Online Channel

13.2.1 Overview

13.2.2 Online Channel: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

13.3 Retail Pharmacies

13.3.1 Overview

13.3.2 Retail Pharmacies: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

14. NORTH AMERICA ANTI-OBESITY DRUGS MARKET - COUNTRY ANALYSIS

14.1 North America

14.1.1 North America Anti-Obesity Drugs Market Revenue and Forecast and Analysis -

by Country

14.1.1.1 North America Anti-Obesity Drugs Market Revenue and Forecast and Analysis - by Country

14.1.2.2 United States: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

14.1.2.2.1 United States: North America Anti-Obesity Drugs Market Share - by Type

14.1.2.2.2 United States: North America Anti-Obesity Drugs Market Share - by Mechanism Of Action

14.1.2.2.3 United States: North America Anti-Obesity Drugs Market Share - by Drug Class

14.1.2.2.4 United States: North America Anti-Obesity Drugs Market Share - by GLP-1 Agonist

14.1.2.2.5 United States: North America Anti-Obesity Drugs Market Share - by Application

14.1.2.2.6 United States: North America Anti-Obesity Drugs Market Share - by Route Of Administration

14.1.2.2.7 United States: North America Anti-Obesity Drugs Market Share - by Distribution Channel

14.2.3.3 Canada: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

14.2.3.3.1 Canada: North America Anti-Obesity Drugs Market Share - by Type

14.2.3.3.2 Canada: North America Anti-Obesity Drugs Market Share - by Mechanism Of Action

14.2.3.3.3 Canada: North America Anti-Obesity Drugs Market Share - by Drug Class

14.2.3.3.4 Canada: North America Anti-Obesity Drugs Market Share - by GLP-1 Agonist

14.2.3.3.5 Canada: North America Anti-Obesity Drugs Market Share - by Application

14.2.3.3.6 Canada: North America Anti-Obesity Drugs Market Share - by Route Of Administration

14.2.3.3.7 Canada: North America Anti-Obesity Drugs Market Share - by Distribution Channel

14.3.4.4 Mexico: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

14.3.4.4.1 Mexico: North America Anti-Obesity Drugs Market Share - by Type

14.3.4.4.2 Mexico: North America Anti-Obesity Drugs Market Share - by Mechanism Of Action

14.3.4.4.3 Mexico: North America Anti-Obesity Drugs Market Share - by Drug Class

14.3.4.4.4 Mexico: North America Anti-Obesity Drugs Market Share - by Glp-1 Agonist

14.3.4.4.5 Mexico: North America Anti-Obesity Drugs Market Share - by Application

14.3.4.4.6 Mexico: North America Anti-Obesity Drugs Market Share - by Route Of Administration

14.3.4.4.7 Mexico: North America Anti-Obesity Drugs Market Share - by Distribution Channel

15 COMPETITIVE LANDSCAPE

15.1 Heat Map Analysis by Key Players

15.2 Company Positioning & Concentration

16 INDUSTRY LANDSCAPE

16.1 Overview

16.2 New Product Development

16.3 Merger and Acquisition

16.4 Other Strategic Developments

17 COMPANY PROFILES

17.1 GSK Plc

17.1.1 Key Facts

17.1.2 Business Description

17.1.3 Products and Services

17.1.4 Financial Overview

17.1.5 SWOT Analysis

17.1.6 Key Developments

17.2 F. Hoffmann-La Roche Ltd

17.2.1 Key Facts

17.2.2 Business Description

17.2.3 Products and Services

17.2.4 Financial Overview

17.2.5 SWOT Analysis

17.2.6 Key Developments

17.3 Teva Pharmaceutical Industries Ltd

17.3.1 Key Facts

17.3.2 Business Description

17.3.3 Products and Services

17.3.4 Financial Overview

- 17.3.5 SWOT Analysis
- 17.3.6 Key Developments
- 17.4 Novo Nordisk AS
 - 17.4.1 Key Facts
 - 17.4.2 Business Description
 - 17.4.3 Products and Services
 - 17.4.4 Financial Overview
 - 17.4.5 SWOT Analysis
 - 17.4.6 Key Developments
- 17.5 Eli Lilly and Co
 - 17.5.1 Key Facts
 - 17.5.2 Business Description
 - 17.5.3 Products and Services
 - 17.5.4 Financial Overview
 - 17.5.5 SWOT Analysis
 - 17.5.6 Key Developments
- 17.6 Sun Pharmaceutical Industries Ltd
 - 17.6.1 Key Facts
 - 17.6.2 Business Description
 - 17.6.3 Products and Services
 - 17.6.4 Financial Overview
 - 17.6.5 SWOT Analysis
 - 17.6.6 Key Developments
- 17.7 VIVUS LLC
 - 17.7.1 Key Facts
 - 17.7.2 Business Description
 - 17.7.3 Products and Services
 - 17.7.4 Financial Overview
 - 17.7.5 SWOT Analysis
 - 17.7.6 Key Developments
- 17.8 Currax Pharmaceuticals LLC.
 - 17.8.1 Key Facts
 - 17.8.2 Business Description
 - 17.8.3 Products and Services
 - 17.8.4 Financial Overview
 - 17.8.5 SWOT Analysis
 - 17.8.6 Key Developments
- 17.9 AdvaCare Pharma USA LLC
 - 17.9.1 Key Facts

- 17.9.2 Business Description
- 17.9.3 Products and Services
- 17.9.4 Financial Overview
- 17.9.5 SWOT Analysis
- 17.9.6 Key Developments
- 17.10 Rhythm Pharmaceuticals Inc
 - 17.10.1 Key Facts
 - 17.10.2 Business Description
 - 17.10.3 Products and Services
 - 17.10.4 Financial Overview
 - 17.10.5 SWOT Analysis
 - 17.10.6 Key Developments

18. APPENDIX

- 18.1 About The Insight Partners

List Of Tables

LIST OF TABLES

- Table 1. North America Anti-Obesity Drugs Market Segmentation
- Table 2. List of Vendors
- Table 3. North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)
- Table 4. North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Type
- Table 5. North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Mechanism Of Action
- Table 6. North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Drug Class
- Table 7. North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Glp-1 Agonist
- Table 8. North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Application
- Table 9. North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Route Of Administration
- Table 10. North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Distribution Channel
- Table 11. North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Country
- Table 12. United States: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Type
- Table 13. United States: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Mechanism Of Action
- Table 14. United States: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Drug Class
- Table 15. United States: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Glp-1 Agonist
- Table 16. United States: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Application
- Table 17. United States: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Route Of Administration
- Table 18. United States: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Distribution Channel
- Table 19. Canada: North America Anti-Obesity Drugs Market - Revenue and Forecast,

2021 - 2031 (US\$ Million) - by Type

Table 20. Canada: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Mechanism Of Action

Table 21. Canada: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Drug Class

Table 22. Canada: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Glp-1 Agonist

Table 23. Canada: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Application

Table 24. Canada: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Route Of Administration

Table 25. Canada: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Distribution Channel

Table 26. Mexico: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Type

Table 27. Mexico: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Mechanism Of Action

Table 28. Mexico: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Drug Class

Table 29. Mexico: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Glp-1 Agonist

Table 30. Mexico: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Application

Table 31. Mexico: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Route Of Administration

Table 32. Mexico: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million) - by Distribution Channel

Table 33. Heat Map Analysis by Key Players

List Of Figures

LIST OF FIGURES

- Figure 1. North America Anti-Obesity Drugs Market Segmentation - Country
- Figure 2. PEST Analysis
- Figure 3. Ecosystem: Anti-Obesity Drugs Market
- Figure 4. North America Anti-Obesity Drugs Market - Key Market Dynamics
- Figure 5. Impact Analysis of Drivers and Restraints
- Figure 6. North America Anti-Obesity Drugs Market Revenue (US\$ Million), 2024 - 2031
- Figure 7. North America Anti-Obesity Drugs Market Share (%) - by Type, 2024 and 2031
- Figure 8. Prescription Drugs: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)
- Figure 9. OTC Drugs: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)
- Figure 10. North America Anti-Obesity Drugs Market Share (%) - by Mechanism Of Action, 2024 and 2031
- Figure 11. Centrally Acting Drugs: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)
- Figure 12. Peripherally Acting Drugs: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)
- Figure 13. Others: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)
- Figure 14. North America Anti-Obesity Drugs Market Share (%) - by Drug Class, 2024 and 2031
- Figure 15. GLP-1 Agonist: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)
- Figure 16. Lipase Inhibitors: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)
- Figure 17. MC4R agonist: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)
- Figure 18. Others: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)
- Figure 19. North America Anti-Obesity Drugs Market Share (%) - by Glp-1 Agonist, 2024 and 2031
- Figure 20. Semaglutide: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)
- Figure 21. Liraglutide: North America Anti-Obesity Drugs Market - Revenue and

Forecast, 2021 - 2031 (US\$ Million)

Figure 22. Tirzepatide (Zepbound): North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 23. North America Anti-Obesity Drugs Market Share (%) - by Application, 2024 and 2031

Figure 24. Appetite Suppression: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 25. Inhibition of Fat Absorption or Digestive Enzymes: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 26. Metabolic Enhancement: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 27. Combination: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 28. North America Anti-Obesity Drugs Market Share (%) - by Route Of Administration, 2024 and 2031

Figure 29. Oral: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 30. Parenteral: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 31. North America Anti-Obesity Drugs Market Share (%) - by Distribution Channel, 2024 and 2031

Figure 32. Hospital Pharmacies: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 33. Online Channel: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 34. Retail Pharmacies: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 35. North America Anti-Obesity Drugs Market Breakdown by Key Countries, 2024 and 2031 (%)

Figure 36. United States: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 37. Canada: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 38. Mexico: North America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US\$ Million)

Figure 39. Company Positioning & Concentration

I would like to order

Product name: North America Anti-Obesity Drugs Market Size and Forecast (2021 - 2031)

Product link: <https://marketpublishers.com/r/N6474F5093FAEN.html>

Price: US\$ 3,450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N6474F5093FAEN.html>